Cardiovascular Sciences, Inc. Agrees to Terms With the University of Central Florida
06 February 2008 - 12:15AM
Marketwired
ORLANDO, FL announced today that following the recent funding
event, the Company has been able to reach an agreement with the
University of Central Florida to continue the Company's research
and development on its post-surgical anti-adhesion technology.
Adhesions occur after surgery when two normally separate but
adjacent tissues that have been injured or stressed scar together.
Adhesions are part of the normal healing process, but when they
occur between tissues that are not normally attached, problems
ranging from mild discomfort to life threatening intestinal
obstruction can occur. The global market to address the problem of
adhesions and adhesion related complications exceeds $6
billion.
To this point, the collaboration between Cardiovascular
Sciences, Inc. and UCF has produced a second-generation material
with physical properties which appear to have exceeded the
initially designed criteria. At surgery, this material is placed
over and between areas likely to produce adhesions and are
gradually degraded and resorbed by the body after the period in
which adhesions are likely to occur, has passed. This next phase in
the Company's development will involve several areas of
investigation. One will be to devise methods to manipulate the
physical characteristics of the material in order to broaden the
range of indications in which the material will be useful. A second
will be to expand the animal trials beyond the proof-of-concept
phase so that data can be gathered to support the requirements to
bring this product to market, first in the veterinary arena and on
to use in human clinical medicine.
Physician and company CEO, Larry Hooper, exclaims, "The further
we have come in this development, the increased number of potential
uses and indications we have encountered. We have received several
inquiries from fields we never expected, expressing to us
additional proposed uses for our technology in areas we did not
have in mind when we started."
Cardiovascular Sciences, Inc. has offices located in the
Research Park adjacent to the UCF campus and is a client company of
the award winning UCF High Tech Incubator program. Gordon Hogan,
the Incubator's Business Development Executive, is quick to praise,
"It is exciting to watch Cardiovascular Sciences leverage their
existing management strengths with the scientific and technological
strengths of UCF. This convergence can easily result in dramatic
changes in the prevention of surgical adhesions."
About Cardiovascular Sciences, Inc.
Cardiovascular Sciences, Inc. is an advanced medical device
company which is developing a novel technology platform to address
the problem of post-surgical and post-traumatic adhesions.
Adhesions and the complications of adhesions are a significant
problem worldwide for a wide range of specialists, including
general surgeons, cardiothoracic surgeons, orthopedic, plastic,
ophthalmologic and otolaryngology specialists to name just some of
them. In addition, the veterinary field has a tremendous need for a
product that can prevent similar problems in a wide variety of
animals.
The Company's unique materials and processes promise a more
cost-effective and decidedly more efficient and capable means to
deal with a problem that has been so devastating to so many.
Current sponsored research at the University of Central Florida
(UCF) and previously at other institutions indicate that The
Company is on the right path and progressing well.
In addition to the anti-adhesion technology, The Company owns
technology in a variety of other areas, including thrombo-resistant
coatings, enhanced intra-arterial balloon pumping catheters, cell
engineered vascular tissues, and a method for improved recovery of
the heart following cardioplegia. This yields a diversified
portfolio with projects in various stages of development.
Forward-looking statements in this release are made pursuant to
the Safe Harbor Provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
certain risks, and uncertainties and actual results could differ
from those discussed. This material is information only and is not
an offer or solicitation to buy or sell the securities.
For more information contact: Cardiovascular Sciences Investor
Relations 800-858-7502 ir@cvsciences.org
Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From Jan 2025 to Feb 2025
Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From Feb 2024 to Feb 2025
